Tier 2 — strong

Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine

Pu Z, Sun Y, Jiang H, Hou Q, Yan H, Wen H, Li G
The American journal of Chinese medicine 2021 49(8):1949-1963

Bibliography

PubMed
PMID 34961418
DOI
10.1142/s0192415x21500920
Funding
Indexed support: Science and Technology Planning Project of Tongxiang; Key Subject funds of Tongxiang. See the publication for grant details.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignRandomized controlled human trial
ModelHuman participants; see population
Sample132 olanzapine-treated patients; 66 per arm
InterventionBerberine versus placebo alongside olanzapine
Duration12 weeks
EndpointsMetabolic or symptom outcomes; Inflammatory markers; Tolerability

What the study showed, in plain terms

The trial reported metabolic and gut-microbiota changes in people with olanzapine-associated disturbances.

Key findings

  • The trial reported metabolic and gut-microbiota changes in people with olanzapine-associated disturbances.

What this study can and cannot tell us

Microbiota composition is not itself a clinical benefit; no long-term psychiatric or cardiovascular outcome was established.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 2
Berberine improves negative symptoms and cognitive function in patients with chronic schizophrenia via anti-inflammatory effect: a randomized clinical trial
Pu Z et al. · Chinese medicine · 2023
Tier 2
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
Chan M et al. · Psychiatry and clinical neurosciences · 2022
Tier 4
Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin
Qiu Y et al. · Asian journal of psychiatry · 2022
Tier 2
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
Li M et al. · European archives of psychiatry and clinical neuroscience · 2022
Tier 2
Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
Li J et al. · Contrast media & molecular imaging · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology